Abstract | BACKGROUND: METHODS: From the electronic databases of the Department of Obstetrics and Gynecology at the Catholic University of the Sacred Heart of Rome and of the S. Orsola Hospital, University of Bologna, a consecutive series of REOC patients were selected using the following inclusion criteria: primary platinum-free interval (PFI-1) of 6 months or longer, completeness of secondary cytoreduction score (CC) of 1 or lower, minimum follow-up period of 48 months, Eastern Cooperative Group (ECOG) performance status at recurrence of 1 or less, and platinum-based HIPEC. Progression-free survival (PFS) and post-relapse survival (PRS) were calculated as the time between SCS + HIPEC and secondary recurrence or death, respectively. RESULTS: The final study population included 70 women with platinum-sensitive REOC. The median follow-up time was 73 months (range 48-128 months), and the median PFI-1 was 19 months (range 6-100 months). At the time of recurrence, the median peritoneal cancer index was 7 (range 1-21), and a CC score of 0 was achieved for 62 patients (88.6 %). As the HIPEC drug, we used oxaliplatin in 17 cases (38.6 %) and cisplatin in 43 cases (61.4 %). No postoperative deaths were observed, and the complication rate for grades 3 and 4 disease was 8.6 %. The median PFS duration was 27 months (range 5-104 months), and the 5- and 7-year PRS rates were respectively 52.8 and 44.7 %, (median PRS 63 months). CONCLUSIONS: The current study demonstrated favorable 5- and 7-year PRS rates for platinum-sensitive REOC patients undergoing SCS + HIPEC, which encourages the inclusion of patients in randomized clinical trials for definitive conclusions to be drawn.
|
Authors | M Petrillo, P De Iaco, S Cianci, M Perrone, B Costantini, C Ronsini, G Scambia, A Fagotti |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 23
Issue 5
Pg. 1660-5
(May 2016)
ISSN: 1534-4681 [Electronic] United States |
PMID | 26714958
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adenocarcinoma, Clear Cell
(mortality, secondary, therapy)
- Adult
- Aged
- Combined Modality Therapy
- Cystadenocarcinoma, Serous
(mortality, secondary, therapy)
- Cytoreduction Surgical Procedures
- Endometrial Neoplasms
(mortality, secondary, therapy)
- Female
- Follow-Up Studies
- Humans
- Hyperthermia, Induced
- Injections, Intraperitoneal
- Middle Aged
- Neoplasm Grading
- Neoplasm Recurrence, Local
(mortality, pathology, therapy)
- Neoplasm Staging
- Ovarian Neoplasms
(mortality, pathology, therapy)
- Platinum
(therapeutic use)
- Prognosis
- Retrospective Studies
- Survival Rate
|